<DOC>
	<DOCNO>NCT00915057</DOCNO>
	<brief_summary>Little known nature extent disturbance hepatic function biliary hepatic clearance chronic viral hepatitis , course disease , functional implication response treatment difficult predict . This study aim assess patient chronic viral hepatitis B ( CHB ) chronic viral hepatitis C ( CHC ) eligible treatment accordance establish consensus guideline involve country . The pharmacokinetics NRL972 determine baseline ( within one month start treatment ) , 3-monthly interval treatment , 12 month ( end treatment ) , 3 6 month end treatment . This provide clearer understand regard use pharmacokinetics NRL972 detect change biliary clearance treatment CHB CHC .</brief_summary>
	<brief_title>Effect Chronic Viral Hepatitis Pharmacokinetics NRL972 .</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Viral , Human</mesh_term>
	<criteria>Chronic viral hepatitis B Adult , male female , age ≥ 18 year &lt; 65 year Body weight ( BW ) : 45 110 kg Body mass index ( BMI ) : 18 30 kg.m2 HBV Serology : HBsAg+ ≥ 6 month ( time application treatment ) Serum ALT ≥ 1.5 time ULN ≥ 6 month ( time application treatment ) Positive liver biopsy within 24 month screen visit Positive biopsy sign active disease ( level activity Knodell , METAVIR ISHAK ) HBV DNA count determine quantitative PCR : ≥ 20,000 IU/mL ALT &lt; 10 time ULN HIVAb negative Noncirrhotic liver disease ( histology within 24 month screen visit ) Not treat chronic viral hepatitis previously ( `` de novo '' i.e . `` naïve '' ) Eligible treatment chronic viral hepatitis accordance national consensus guideline pertinent country site conduct trial Willing able provide inform consent Chronic viral hepatitis C Adult , male female , age ≥ 18 year &lt; 65 year Body weight ( BW ) : 45 110 kg Body mass index ( BMI ) : 18 30 kg.m2 HCVAb+ ≥ 6 month ( time application treatment ) HCV RNA count &gt; 10,000 U/L quantitative PCR assay within last 6 month ( time application treatment ) Positive liver biopsy within 24 month application treatment Positive biopsy sign fibrotic disease ( level fibrosis METAVIR ≥ F1 ISHAK ≥ F2 ) ALT &lt; 10 time ULN HIVAb negative Noncirrhotic liver disease ( histology within 24 month screen visit ) Not treat chronic viral hepatitis previously ( `` de novo '' i.e . `` naïve '' ) Eligible treatment chronic viral hepatitis accordance national consensus guideline pertinent country site conduct trial Willing able provide inform consent Chronic viral hepatitis C plus chronic viral hepatitis B Patients combine CHB CHC manage ( term eligibility standard treatment accordance hepatitis type predominant viral replication . Trial specific criterion : CHB , CHC &amp; CHB+CHC Previous participation trial Participation clinical trial within 30 day entry protocol Treatment investigational drug within 30 day entry protocol Nonresponse previous treatment chronic viral hepatitis Relapse previous treatment chronic viral hepatitis Any know cause liver disease chronic viral hepatitis B and/or C , include limited hepatitis D , haemochromatosis , alpha1antitrypsin deficiency , Wilson 's disease , autoimmune hepatitis , drugrelated liver disease Evidence advance liver disease , history presence ascites , bleed varix , encephalopathy Patients organ transplant Hypersensitivity prospective standard treatment Any relevant comorbidity , instance , limited : Limiting uncompensated psychiatric condition ( e.g . severe depression , history severe psychiatric disorder ) CNS trauma seizure disorder require medication Significant cardiovascular dysfunction within past 6 month ( e.g . angina , congestive cardiac failure , recent myocardial infarction , severe hypertension significant arrhythmia ) Patients ECG show clinically significant abnormality Poorly control diabetes mellitus Patients haemodialysis Daily use &gt; 40 g alcohol Positive alcohol test SCRvisit Evidence suspicion social drug abuse Positive drug test SCRvisit Use prohibit medication Suspicion evidence subject trustworthy reliable Suspicion evidence subject able make free consent understand information regard Criteria specifically related standard treatment chronic viral hepatitis Relevant clinical laboratory test abnormality , instance , limited : Haemoglobin ( Hgb ) &lt; 11 g dL1 woman &lt; 13 g dL1 men White Blood Cell count ( WBC ) &lt; 3,000 10 exp9/mL Granulocyte count &lt; 1,500 10 exp9/mL Lymphocyte count &lt; 500 10 exp9/mL Platelets &lt; 75,000 10 exp9/mL Prothrombin time INR &gt; 1.4 Bilirubin &gt; 25 micromol/L ( except functional hyperbilirubinaemia ) Albumin &lt; 35 g/L Serum creatinine &gt; 133 micromol/L Fasting blood glucose &gt; 7.4 mmol/L nondiabetic patient HbA1c &gt; 7 % diabetic patient Positive autoimmune antibody TSH outside normal range ( patient intend interferon ) Relevant comorbidity , instance , limited : Limiting uncompensated chronic pulmonary disease ( e.g . chronic obstructive pulmonary disease ) Any medical condition requiring , likely require course study , chronic systemic administration steroid Gout ( patient intend interferon ) Immunologically mediate disease ( e.g . inflammatory bowel disease , Crohn 's disease , ulcerative colitis , rheumatoid arthritis , idiopathic thrombocytopenic purpura , systemic lupus erythematosus , autoimmune haemolytic anaemia , scleroderma , severe psoriasis , cryoglobulinaemia vasculitis ) ( patient intend interferon ) Patients clinically significant retinal abnormality ( patient intend interferon ) All female Positive pregnancy test Lactating Not use medically appropriate contraception and/or willing maintain contraception treatment chronic viral hepatitis 6 month thereafter</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2009</verification_date>
</DOC>